0.20
+0.0963(+92.77%)
Currency In USD
| Previous Close | 0.1 |
| Open | 0.28 |
| Day High | 0.32 |
| Day Low | 0.2 |
| 52-Week High | 3.1 |
| 52-Week Low | 0.1 |
| Volume | 3.36M |
| Average Volume | 761,635 |
| Market Cap | 3.44M |
| PE | -0.12 |
| EPS | -1.63 |
| Moving Average 50 Days | 0.66 |
| Moving Average 200 Days | 1.23 |
| Change | 0.1 |
If you invested $1000 in Unity Biotechnology, Inc. (UBX) since IPO date, it would be worth $1.2 as of January 10, 2026 at a share price of $0.2. Whereas If you bought $1000 worth of Unity Biotechnology, Inc. (UBX) shares 5 years ago, it would be worth $3.33 as of January 10, 2026 at a share price of $0.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates
GlobeNewswire Inc.
May 05, 2025 12:00 PM GMT
UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients enterin
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
GlobeNewswire Inc.
May 01, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will prese
UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME
GlobeNewswire Inc.
Apr 23, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the peer-reviewed jo